Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis
Ariel López-Chávez, Todd Young, Sophie Fages et al. · Journal of Thoracic Oncology · 2012
Cited by 54 works. doi:10.1097/jto.0b013e318265b500
Authors
- Ariel López-Chávez
- Todd Young
- Sophie Fages
- Joan H. Schiller
- Afshin Dowlati
- Julie Renee Brahmer
- David H. Johnson
- Alan Sandler
References
- Global cancer statistics
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.
- Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma